Proinflammatory cytokine HMGB1 is increased in serum of MM patients, since it drives and sustains MM development and it was proposed as an early detection biomarker and a possible drug target in MM [29, 30]. This evidence concerns the gene HMGB1 and Miyoshi myopathy.